{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:27:25Z","timestamp":1760218045568,"version":"3.37.3"},"reference-count":37,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Treatment decisions in primary myelofibrosis (PMF) are guided by numerous prognostic systems. Patient-specific comorbidities have influence on treatment-related survival and are considered in clinical contexts but have not been routinely incorporated into current prognostic models. We hypothesized that patient-specific comorbidities would inform prognosis and could be incorporated into a quantitative score. All patients with PMF or secondary myelofibrosis with available DNA and comprehensive electronic health record (EHR) data treated at Vanderbilt University Medical Center between 1995 and 2016 were identified within Vanderbilt\u2019s Synthetic Derivative and BioVU Biobank. We recapitulated established PMF risk scores (eg, Dynamic International Prognostic Scoring System [DIPSS], DIPSS plus, Genetics-Based Prognostic Scoring System, Mutation-Enhanced International Prognostic Scoring System 70+) and comorbidities through EHR chart extraction and next-generation sequencing on biobanked peripheral blood DNA. The impact of comorbidities was assessed via DIPSS-adjusted overall survival using Bonferroni correction. Comorbidities associated with inferior survival include renal failure\/dysfunction (hazard ratio [HR], 4.3; 95% confidence interval [95% CI], 2.1-8.9; P\u00a0= .0001), intracranial hemorrhage (HR, 28.7; 95% CI, 7.0-116.8; P\u00a0= 2.83e-06), invasive fungal infection (HR, 41.2; 95% CI,\u00a07.2-235.2; P\u00a0= 2.90e-05), and chronic encephalopathy (HR, 15.1; 95% CI, 3.8-59.4; P\u00a0=\u00a0.0001). The extended DIPSS model including all 4 significant comorbidities showed a significantly higher discriminating power (C-index 0.81; 95% CI, 0.78-0.84) than the original DIPSS model (C-index 0.73; 95% CI, 0.70-0.77). In summary, we repurposed an institutional biobank to identify and risk-classify an uncommon hematologic malignancy by established (eg, DIPSS) and other clinical and pathologic factors (eg, comorbidities) in an unbiased fashion. The inclusion of comorbidities into risk evaluation may augment prognostic capability of future genetics-based scoring systems.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006318","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T14:52:14Z","timestamp":1649947934000},"page":"756-767","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Patient-specific comorbidities as prognostic variables for survival in\u00a0myelofibrosis"],"prefix":"10.1182","volume":"7","author":[{"given":"Andrew L.","family":"Sochacki","sequence":"first","affiliation":[{"name":"1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5107-0584","authenticated-orcid":false,"given":"Cosmin Adrian","family":"Bejan","sequence":"additional","affiliation":[{"name":"2Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilin","family":"Zhao","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN"},{"name":"4Center for Quantitative Sciences, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameet","family":"Patel","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwin","family":"Kishtagari","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis P.","family":"Spaulding","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8255-3140","authenticated-orcid":false,"given":"Alexander J.","family":"Silver","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN"},{"name":"5Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon S.","family":"Stockton","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Pugh","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8901-6281","authenticated-orcid":false,"given":"R. Dixon","family":"Dorand","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manasa","family":"Bhatta","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4704-7124","authenticated-orcid":false,"given":"Nicholas","family":"Strayer","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN"},{"name":"3Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN"},{"name":"4Center for Quantitative Sciences, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4254-3794","authenticated-orcid":false,"given":"Christina A.","family":"Snider","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3602-9994","authenticated-orcid":false,"given":"Thomas","family":"Stricker","sequence":"additional","affiliation":[{"name":"6Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziz","family":"Nazha","sequence":"additional","affiliation":[{"name":"7Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander G.","family":"Bick","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN"},{"name":"5Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN"},{"name":"8Center for Immunobiology, Vanderbilt University School of Medicine, Nashville, TN"},{"name":"9Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3752-4006","authenticated-orcid":false,"given":"Yaomin","family":"Xu","sequence":"additional","affiliation":[{"name":"2Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN"},{"name":"3Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN"},{"name":"4Center for Quantitative Sciences, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3763-5504","authenticated-orcid":false,"given":"Michael R.","family":"Savona","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN"},{"name":"5Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN"},{"name":"8Center for Immunobiology, Vanderbilt University School of Medicine, Nashville, TN"},{"name":"9Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"issue":"20","key":"2023081515552672800_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2023081515552672800_bib2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"issue":"16","key":"2023081515552672800_bib3","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2023081515552672800_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"25","key":"2023081515552672800_bib5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2023081515552672800_bib6","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"2","key":"2023081515552672800_bib7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"13","key":"2023081515552672800_bib8","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2023081515552672800_bib9","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A\u00a0dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2023081515552672800_bib10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"2023081515552672800_bib11","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V124.21.406.406","article-title":"Integration of mutations and karyotype towards a genetics-based prognostic scoring system (GPSS) for primary myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2023081515552672800_bib12","first-page":"405","article-title":"Mutation-enhanced international prognostic scoring system (MIPSS) for primary myelofibrosis: an","volume":"124","author":"Vannucchi","year":"2014","journal-title":"AGIMM & IWG-MRT project"},{"issue":"4","key":"2023081515552672800_bib13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2023081515552672800_bib14","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023081515552672800_bib15","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"15","key":"2023081515552672800_bib16","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023081515552672800_bib17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ajh.23675","article-title":"Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes","volume":"89","author":"Daver","year":"2014","journal-title":"Am J Hematol"},{"issue":"16","key":"2023081515552672800_bib18","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2010.31.3353","article-title":"Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model","volume":"29","author":"Naqvi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2023081515552672800_bib19","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/cncr.28857","article-title":"Comorbidities predict worse prognosis in patients with primary myelofibrosis","volume":"120","author":"Newberry","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"2023081515552672800_bib20","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s12032-014-0869-8","article-title":"Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis","volume":"31","author":"Lekovic","year":"2014","journal-title":"Med Oncol"},{"issue":"7","key":"2023081515552672800_bib21","doi-asserted-by":"crossref","first-page":"e0175508","DOI":"10.1371\/journal.pone.0175508","article-title":"Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record","volume":"12","author":"Wei","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"2023081515552672800_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/clpt.2008.89","article-title":"Development of a large-scale de-identified DNA biobank to enable personalized medicine","volume":"84","author":"Roden","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"2023081515552672800_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jbi.2014.02.003","article-title":"Secondary use of clinical data: the Vanderbilt approach","volume":"52","author":"Danciu","year":"2014","journal-title":"J\u00a0Biomed Inform"},{"issue":"4","key":"2023081515552672800_bib24","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ajhg.2010.03.003","article-title":"Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record","volume":"86","author":"Ritchie","year":"2010","journal-title":"Am J Hum Genet"},{"issue":"13","key":"2023081515552672800_bib25","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.112.000604","article-title":"Genome- and phenome-wide analysis of cardiac conduction identifies markers of arrhythmia risk","volume":"127","author":"Ritchie","year":"2013","journal-title":"Circulation"},{"issue":"12","key":"2023081515552672800_bib26","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nbt.2749","article-title":"Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data","volume":"31","author":"Denny","year":"2013","journal-title":"Nat Biotechnol"},{"year":"2015","author":"Harrell","key":"2023081515552672800_bib27"},{"issue":"9","key":"2023081515552672800_bib28","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/bioinformatics\/btq126","article-title":"PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations","volume":"26","author":"Denny","year":"2010","journal-title":"Bioinformatics"},{"issue":"17","key":"2023081515552672800_bib29","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1001\/jama.2011.1558","article-title":"Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies","volume":"306","author":"Sorror","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"2023081515552672800_bib30","first-page":"256","article-title":"Idiopathic myelofibrosis with extramedullary hematopoiesis in the kidneys","volume":"52","author":"Schnuelle","year":"1999","journal-title":"Clin Nephrol"},{"issue":"8","key":"2023081515552672800_bib31","first-page":"1438","article-title":"Extramedullary haematopoeisis in the renal parenchyma as a cause of acute renal failure in myelofibrosis","volume":"10","author":"Holt","year":"1995","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2023081515552672800_bib32","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.ajkd.2017.06.022","article-title":"Membranous nephropathy and intrarenal extramedullary hematopoiesis in a patient with myelofibrosis","volume":"70","author":"Philipponnet","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2023081515552672800_bib33","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1053\/ajkd.2001.27730","article-title":"Acute renal failure secondary to spontaneous acute tumor lysis syndrome in myelofibrosis","volume":"38","author":"Sile","year":"2001","journal-title":"Am J Kidney Dis"},{"issue":"17","key":"2023081515552672800_bib34","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2169\/internalmedicine.8706-16","article-title":"Tumor lysis syndrome after the administration of ruxolitinib in a patient with post-polycythemia vera myelofibrosis","volume":"56","author":"Koshiishi","year":"2017","journal-title":"Intern Med"},{"issue":"1","key":"2023081515552672800_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.24572","article-title":"Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507\u00a0patients","volume":"92","author":"Polverelli","year":"2017","journal-title":"Am J Hematol"},{"issue":"2","key":"2023081515552672800_bib36","first-page":"245","article-title":"Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders","volume":"89","author":"Garypidou","year":"2004","journal-title":"Haematologica"},{"issue":"137","key":"2023081515552672800_bib37","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1183\/16000617.0041-2015","article-title":"Pulmonary hypertension in patients with chronic myeloproliferative disorders","volume":"24","author":"Adir","year":"2015","journal-title":"Eur Respir Rev"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/5\/756\/2071425\/blooda_adv-2021-006318-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/5\/756\/2071425\/blooda_adv-2021-006318-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T16:12:18Z","timestamp":1692115938000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/5\/756\/484926\/Patient-specific-comorbidities-as-prognostic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,3,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006318","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2023,3,2]]}}}